← Leaderboards
Howard I Scher
Sloan-Kettering Institute For Cancer Res
$6,446,552
Attributed
$7,342,811
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,758,983 · 14
By mechanism
P50$36,909,019 · 11
U01$1,792,519 · 1
P01$1,732,169 · 1
R21$325,276 · 1
Top collaborators
- Maria E Arcila5 shared
- Yu Chen3 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Jeffrey Boyd$5,544,717
- George J. Bosl$8,065,724
- Ronald A Ghossein$1,209,516
- Derek S Tan$22,003,139
- Raju Chaganti$3,696,551
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateMemorial Sloan-Kettering Cancer CenterProgramsResearch Project GrantsResearch PersonnelAndrogen ReceptorMalignant NeoplasmsTranslational ResearchBaseTumorResistanceBiological MarkersReportingBloodMolecularProstateFundingMeetingsCommunitiesEnsurePublicationsInstitutionClinical TrialsCollaborations
Grant awards (53)
Core A: Administrative Core$212,658
P50 · FY2025 · CA · contact PI
Developmental Research Program$212,657
P50 · FY2025 · CA · contact PI
Core E:Biomarkers Core$212,657
P50 · FY2025 · CA · contact PI
SPORE in Prostate Cancer$1,773,356
P50 · FY2024 · CA · contact PI
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers$330,695
P01 · FY2024 · CA · contact PI
Evaluation of the effect of patient-context factors and sample acquisition on the quality and analytical performance of cell-free DNA and circulating tumor cells profiling assays in prostate cancer pa$189,163
U01 · FY2024 · CA
Core E:Biomarkers Core$161,198
P50 · FY2024 · CA · contact PI
Core A: Administrative Core$121,271
P50 · FY2024 · CA · contact PI
Developmental Research Program$88,001
P50 · FY2024 · CA · contact PI
SPORE in Prostate Cancer$2,345,974
P50 · FY2023 · CA · contact PI
Evaluation of the effect of patient-context factors and sample acquisition on the quality and analytical performance of cell-free DNA and circulating tumor cells profiling assays in prostate cancer pa$396,790
U01 · FY2023 · CA
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers$340,907
P01 · FY2023 · CA · contact PI
Core E:Biomarkers Core$212,402
P50 · FY2023 · CA · contact PI
Core A: Administrative Core$159,300
P50 · FY2023 · CA · contact PI
Developmental Research Program$115,052
P50 · FY2023 · CA · contact PI
SPORE in Prostate Cancer$2,364,931
P50 · FY2022 · CA · contact PI
Evaluation of the effect of patient-context factors and sample acquisition on the quality and analytical performance of cell-free DNA and circulating tumor cells profiling assays in prostate cancer pa$396,790
U01 · FY2022 · CA
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers$340,907
P01 · FY2022 · CA · contact PI
Core E:Biomarkers Core$213,993
P50 · FY2022 · CA · contact PI
Core A: Administrative Core$164,610
P50 · FY2022 · CA · contact PI
Developmental Research Program$123,458
P50 · FY2022 · CA · contact PI
SPORE in Prostate Cancer$797,371
P50 · FY2021 · CA · contact PI
Evaluation of the effect of patient-context factors and sample acquisition on the quality and analytical performance of cell-free DNA and circulating tumor cells profiling assays in prostate cancer pa$404,888
U01 · FY2021 · CA
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers$349,880
P01 · FY2021 · CA · contact PI
Core F: Administrative Core$63,979
P50 · FY2021 · CA · contact PI
SPORE in Prostate Cancer$2,314,241
P50 · FY2020 · CA · contact PI
Evaluation of the effect of patient-context factors and sample acquisition on the quality and analytical performance of cell-free DNA and circulating tumor cells profiling assays in prostate cancer pa$404,888
U01 · FY2020 · CA
Core F: Administrative Core$150,698
P50 · FY2020 · CA · contact PI
Development Research Program$128,173
P50 · FY2020 · CA · contact PI
SPORE in Prostate Cancer$2,311,094
P50 · FY2019 · CA · contact PI
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers$369,780
P01 · FY2019 · CA · contact PI
Core F: Administrative Core$152,302
P50 · FY2019 · CA · contact PI
Development Research Program$131,301
P50 · FY2019 · CA · contact PI
SPORE in Prostate Cancer$2,436,043
P50 · FY2018 · CA · contact PI
Core F: Administrative Core$159,685
P50 · FY2018 · CA · contact PI
Development Research Program$136,852
P50 · FY2018 · CA · contact PI
SPORE in Prostate Cancer$2,436,043
P50 · FY2017 · CA · contact PI
Core F: Administrative Core$160,796
P50 · FY2017 · CA · contact PI
Development Research Program$138,873
P50 · FY2017 · CA · contact PI
SPORE in Prostate Cancer$2,349,999
P50 · FY2016 · CA · contact PI
Core F: Administrative Core$149,395
P50 · FY2016 · CA · contact PI
Development Research Program$123,536
P50 · FY2016 · CA · contact PI
SPORE In Prostate Cancer$1,901,412
P50 · FY2015 · CA · contact PI
SPORE In Prostate Cancer$1,881,400
P50 · FY2014 · CA · contact PI
SPORE In Prostate Cancer$1,871,390
P50 · FY2013 · CA · contact PI
SPORE In Prostate Cancer$2,001,488
P50 · FY2012 · CA · contact PI
SPORE In Prostate Cancer$1,901,414
P50 · FY2011 · CA · contact PI
SPORE in Prostate Cancer$2,365,008
P50 · FY2010 · CA · contact PI
SPORE in Prostate Cancer$2,365,008
P50 · FY2009 · CA · contact PI
MECHANISM BASED THERAPY FOR PROSTATE CANCER$0
P50 · FY2002 · CA
MECHANISM BASED THERAPY FOR PROSTATE CANCER$0
P50 · FY2002 · CA
MECHANISM BASED THERAPY FOR PROSTATE CANCER$0
P50 · FY2001 · CA
BIOLOGIC EFFECTS OF 17AA GELDANAMYCIN$325,276
R21 · FY2000 · CA